Follow The Filings

RCEL Avita Medical Inc.

Health Care, filed as AVITA MEDICAL INC (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by RCEL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RCEL insider trades
  • $235K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. David D O'Toole CFO
    Buy
    $7,940 2,000 shares at $3.97 +1.3% to stake
    Traded Jun 12 Filed Aug 24
    ↗
  2. Joseph Fralin Woody Director
    Buy
    $21K 5,200 shares at $4.00 +5.1% to stake
    Traded Jun 9 Filed Jun 10
    ↗
  3. Joseph Fralin Woody Director
    Buy
    $42K 10,000 shares at $4.19 +11% to stake
    Traded Jun 9 Filed Jun 9
    ↗
  4. Joseph Fralin Woody Director
    Buy
    $41K 10,000 shares at $4.09 +12% to stake
    Traded Jun 3 Filed Jun 5
    ↗
  5. Joseph Fralin Woody Director
    Buy
    $85K 20,000 shares at $4.25 New stake
    Traded Jun 1–2 Filed Jun 3
    ↗
  6. David D O'Toole CFO
    Buy
    $8,520 2,000 shares at $4.26 +1.4% to stake
    Traded May 20 Filed May 20
    ↗
  7. David D O'Toole CFO
    Buy
    $8,480 2,000 shares at $4.24 +1.4% to stake
    Traded May 19 Filed May 19
    ↗
  8. David D O'Toole CFO
    Buy
    $8,604 1,800 shares at $4.78 +1.3% to stake
    Traded Mar 11 Filed Mar 11
    ↗
  9. David D O'Toole CFO
    Buy
    $12K 3,000 shares at $4.15 +2.2% to stake
    Traded Feb 19 Filed Feb 23
    ↗

Also filed in the last 12 months, not counted as buying or selling: 12 stock grants.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 1.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K/A 5.07 Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 5.02,5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
DEF 14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,1.02,2.02,2.03,3.02,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 1.01,2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $63.89M $70.88M
Gross profit $42.36M $55.16M $58.82M
Gross margin * — 86.3% 83.0%
Net income -$35.38M -$61.84M -$48.59M
Net margin * — -96.8% -68.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $104.01M $57M $35.49M
Total non-current assets * $7.63M $22.71M $20.9M
Total assets $111.64M $79.71M $56.39M
Total current liabilities $13.2M $20.16M $62.68M
Total non-current liabilities * $48.69M $54.81M $10.36M
Total equity $49.06M $4.5M -$16.65M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$38.01M -$48.94M -$31.2M
Cash from investing $1.61M $37.36M $12.45M
Cash from financing $40.37M $3.51M $14.94M
Net change in cash $3.95M -$8.07M -$3.81M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.